VALUE PROPOSITION

Onco-PDO is potentially optimised to:

- have consistent organoid formation in multiple cancer tumours (biobank)
- functionally, cellularly, and molecularly similar to cancer tumours residing in body (physiological relevant)
- improve preclinical testing and pharmacological compound or drug validation by assessing efficacy and safety (high-throughput screening)
- obtain drug efficacy and safety data prior to administering drugs (medical intervention)
- address inter-individual human population variability (patient-specific response)
Onco-PDO ANALYTICS TESTING

A biopsy of the tumor is taken from routine surgery

A Cancer Avatar is created

High-throughput drug screening

Stratification of drug responses

Obtain data on drugs efficacy or adverse effect data over longer culture periods

Cell selection and expansion

Add drugs X Y Z
Onco-PDO is potentially optimised to:

- have consistent organoid formation in multiple cancer tumours (biobank)
- functionally, cellularly, and molecularly similar to cancer tumours residing in body (physiological relevant)
- improve preclinical testing and pharmacological compound or drug validation by assessing efficacy and safety (high-throughput screening)
- obtain drug efficacy and safety data prior to administering drugs (medical intervention)
- address inter-individual human population variability (patient-specific response)